Oral as a tag covers the full slate of oral peptide and oral peptide-alternative drug stories. The successful examples — oral semaglutide, oral Wegovy, icotrokinra (J&J's oral psoriasis peptide) — depend on permeation enhancers, while small-molecule oral GLP-1s like orforglipron / Foundayo sidestep the peptide-stability problem entirely.
Coverage on this site includes oral GLP-1 launches and head-to-heads, oral insulin platform work, oral inflammatory-disease peptides, and the broader formulation chemistry behind what makes a peptide drug bioavailable by mouth.
Stories here cover platform launches, head-to-head data, and the small-molecule alternatives. See #oral-peptide, #oral-glp-1, and #drug-delivery for narrower threads.
IQVIA tracking data reported April 21 showed Eli Lilly's newly-launched oral GLP-1 Foundayo (orforglipron) drew 1,390 prescriptions in its first full week (April 6-10), roughly 45% of the 3,071 Wegovy pill scripts in Novo Nordisk's launch week in January. Analyst consensus requires Foundayo to hit about 5.4 million prescriptions from April-December to generate $1.7 billion in 2026 revenue — a target that looks challenging at the current trajectory.
The FDA approved Foundayo, a once-daily oral GLP-1 pill that can be taken any time without food or water restrictions. In trials, patients lost an average of 11% body weight over one year. It was approved under the FDA's National Priority Voucher program.
Eli Lilly's oral GLP-1 drug orforglipron is among the most consequential FDA decisions in Q2 2026. Analysts expect it to help Lilly's tirzepatide franchise exceed $100 billion in peak revenue.